Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
Tango Therapeutics reported updated Phase 1/2 data for vopimetostat plus Revolution Medicines' daraxonrasib in MTAP-deleted/RAS-mutant pancreatic cancer, showing an 82% objective response rate, median PFS not yet reached, and 88% of patients progression-free at 9 months across 22 efficacy-evaluable 2L/3L patients. The combination was generally well-tolerated at dose level 1, with no dose-limiting toxicities, no treatment-related withdrawals, and no Grade 4 or 5 adverse events; the vopimetostat plus zoldonrasib arm showed a 54% ORR and 61% 9-month PFS.
Key figures
- Drug Name
- vopimetostat (TNG462)
- Phase Of Trial
- Phase 1/2
- Orr nsclc
- 80% (4/5)
- Orr zoldonrasib
- 54% (19/35)
- Dcr daraxonrasib
- 100%
- Phase3 initiation
- 1H 2027
- Pfs 9mo zoldonrasib
- 61%
- Pfs 9mo daraxonrasib
- 88%
- Orr daraxonrasib pdac
- 82% (18/22)
- Grade3 trae rate dose1
- 40% (10/25)
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.